arrow
C

Chia-Jung Busch

university medicine greifswald
H指数:30
被引数:3,220

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Automated Sinus MRI Phenotyping with PARASIDE: Construct-Specific Validation Against Independent Manual Annotations and Radiological Assessments in a Population-Based Cohort

基于PARASIDE的自动化鼻窦MRI表型分析:在基于人群队列中针对独立手动注释和放射学评估的构念特异性验证

2026-10-280
OA
Retrospective screening for congenital cytomegalovirus infection in the Survey of Neonates in Pomerania shows very low disease burden

对波美拉尼亚新生儿调查中先天性巨细胞病毒感染的回顾性筛查显示疾病负担极低

2026-04-100
OA
UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial

UV1疫苗接种在经帕博利珠单抗治疗、患有复发性或转移性头颈癌患者中的效果:一项随机多中心II期临床试验

Med
IF11.8
2025-04-110
PRE
Nivolumab (NIVO) in the first-line (1L) or second-line (2L) and later (2L+) settings in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from the German non-interventional study (NIS), HANNA

纳武利尤单抗(NIVO)在复发性/或转移性头颈鳞状细胞癌(R/M SCCHN)患者中的一线(1L)或二线(2L)及后续(2L+)治疗中的应用:来自德国非干预性研究(NIS)HANNA的更新结果

2024-09-010
PRE
Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial

癌症疫苗UV1在计划接受pembrolizumab一线治疗的复发或转移性PD-L1阳性头颈部鳞状细胞癌患者中的耐受性和有效性-随机2期重点试验

2024-02-073
OAAI
Patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab (NIVO) in the first-line (1L) or later-line (2L+) settings in Germany: Updated results from the real-world HANNA study
2023-10-010
OAAI
Detection of stage I HPV-driven oropharyngeal cancer in asymptomatic individuals in the Hamburg City Health Study using HPV16 E6 serology - A proof- of-concept study

在汉堡市健康研究中使用HPV16 E6血清学检测无症状个体中I期HPV驱动的口咽癌-概念验证研究

2022-11-0113
OAAI
HANNA: Real-world data of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), including first-line population, treated with nivolumab in Germany
2022-09-012
OAAI
Patient derived ex vivo tissue slice cultures demonstrate a profound DNA double-strand break repair defect in HPV-positive oropharyngeal head and neck cancer
2022-03-0112
PRE
Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src family kinases as prognostic markers and potential targets (vol 1, 149, 2021)
2022-02-110
OA